Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424656 | 0.83 | ALDH1A1 (0.59) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27721562 | 0.80 | KMT2A (0.56) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27353957 | 0.79 | ALDH1A1 (0.51) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL25067265 | 0.78 | TLR8 (0.59) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL3307602 | 0.77 | ALDH1A1 (0.53) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL28078170 | 0.77 | TLR8 (0.57) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL18250324 | 0.77 | TLR8 (0.57) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL5824074 | 0.77 | TLR8 (0.57) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27679742 | 0.75 | KMT2A (0.54) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 | |
| SCHEMBL1466191 | 0.75 | ALDH1A1 (0.54) | ALDH1A1POLBKMT2ATLR8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
| CN-101778857-A | Platinum (IV) complex compound | PLATCO TECHNOLOGIES PROPRIETAR | 2010-07-14 | — | — | CN | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | ALDH1A1 3109/4885POLB 225/4885KMT2A 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.